ApoA-I Milano

PBB Protein APOA1 image

ApoA-I Milano is a naturally occurring mutant form of the apolipoprotein A-I protein, which is a major component of high-density lipoprotein (HDL) in the blood. This variant was first identified in a small population in Limone sul Garda, a village in northern Italy, and is named after the city of Milan where it was discovered.

Discovery and Genetics

ApoA-I Milano was discovered in 1974 by Dr. Cesare Sirtori and his colleagues. The mutation involves a substitution of the amino acid arginine for cysteine at position 173 of the apolipoprotein A-I protein. This single amino acid change significantly alters the protein's structure and function.

Function and Mechanism

ApoA-I Milano is associated with a reduced risk of cardiovascular disease despite low levels of HDL cholesterol. The protein is believed to enhance the process of reverse cholesterol transport, where cholesterol is removed from tissues and transported to the liver for excretion. This process helps to prevent the buildup of cholesterol in the arteries, reducing the risk of atherosclerosis.

Clinical Significance

Individuals carrying the ApoA-I Milano mutation have been observed to have a lower incidence of cardiovascular events. Research has shown that this variant can lead to the formation of larger and more effective HDL particles, which are better at removing cholesterol from the body. Studies are ongoing to explore the potential therapeutic applications of ApoA-I Milano in treating cardiovascular diseases.

Research and Development

Several pharmaceutical companies have been investigating the potential of ApoA-I Milano as a treatment for cardiovascular diseases. Clinical trials have been conducted to assess the safety and efficacy of synthetic versions of the protein. These studies aim to replicate the beneficial effects observed in individuals with the natural mutation.

See Also

• Apolipoprotein A-I
• High-density lipoprotein
• Cardiovascular disease
• Reverse cholesterol transport
• Atherosclerosis